Accelerated Development of Self-Amplifying mRNA (saRNA) Vaccines

Time: 2:45 pm
day: Day One


  • Self-amplifying RNAs (saRNA) have the potential to elicit effective immune response at lower doses compared to non-replicating mRNA vaccines
  • saRNAs are inherently more fragile than mRNA and are prone to degradation and needs to be packaged in lipid nanoparticles (LNP) to be used as vaccine candidates
  • Typical high shear LNP manufacturing methods affect the potency; hence, low shear robust manufacturing methods are needed for rapid screening of preclinical vaccine candidates and then to swiftly advance the lead candidates to GMP-enabling studies as required
  • Demonstrating the utility of a genomic medicine toolkit, including a proprietary lipid reagent library in a microfluidic-based nanoparticle manufacturing platform using a unique vector design